HbA2 Leuven and Its Impact on HbA1c Results

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01909648

Acronym

HbA2 Leuven

Enrollment

Registered

2013-07-26

Start date

2013-09-30

Completion date

2014-02-28

Last updated

2015-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Family Study HbA2 Leuven Mutation.

Brief summary

The study is designed to demonstrate HbA2 Leuven mutation and to asssess its impact on routine HbA1c measurements.

Detailed description

HbA2 Leuven mutation will be investigated using molecular diagnostic techniques. Interference on HbA1c measurements will be assessed in HbA2 Leuven carriers using different methodologies.

Interventions

OTHERBlood withdrawal

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Family history of HbA2 Leuven mutation.

Exclusion criteria

* Any condition inhibiting simple blood withdrawal.

Design outcomes

Primary

Measure	Time frame
Demonstration of presence/absence of HbA2 Leuven mutation	1 year

Secondary

Measure	Time frame
Demonstration of impact of HbA2 Leuven mutation on routine HbA1c measurements	1 year

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026